Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial.
D054058:Acute Coronary Syndrome / Q000150:complications* / Q000401:mortality / Q000503:physiopathology*; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D015716:Electrocardiography, Ambulatory; D017984:Enoxaparin / Q000627:therapeutic use; D000077542:Eptifibatide; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology* / Q000503:physiopathology; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011379:Prognosis; D012008:Recurrence; D018570:Risk Assessment
D000925:Anticoagulants; D017984:Enoxaparin; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D000077542:Eptifibatide